Mary C Zanarini1, Frances R Frankenburg, D Bradford Reich, Lindsey C Conkey, Garrett M Fitzmaurice. 1. The authors are with the Laboratory for the Study of Adult Development, McLean Hospital, Belmont, Massachusetts (e-mail: zanarini@mclean.harvard.edu ). Dr. Zanarini, Dr. Reich, and Dr. Fitzmaurice are also with the Department of Psychiatry, Harvard Medical School, Boston. Dr. Frankenburg is also with the Department of Psychiatry, Boston University School of Medicine, Boston.
Abstract
OBJECTIVE: The goal of this study was to document the use of 16 treatment modalities reported by 290 patients with borderline personality disorder and 72 patients with other axis II disorders over 16 years of prospective follow-up. METHODS: This study built upon previous findings of the McLean Study of Adult Development. Treatment use was assessed at baseline and at eight two-year follow-up periods with a semistructured interview of proven reliability and validity. RESULTS: Patients with borderline personality disorder reported significantly higher rates of use of 12 of the 16 treatment modalities studied. Only four of the 16 treatment modalities were used by roughly the same percentage of patients with borderline personality disorder and those with other axis II disorders: individual therapy, intensive individual therapy, couples or family therapy, and electroconvulsive therapy. In addition, rates of participation in 13 treatment modalities declined significantly over the first eight years of follow-up for those in both study groups. However, the rates of participation in 15 of 16 treatment modalities did not decline significantly over the second eight years of follow-up for those in either study group. CONCLUSIONS: The results of this study suggest that rates of treatment use by patients with borderline personality disorder decline significantly over the short and medium term. They also suggest that these rates remain stable or fail to decline further over the longer term.
OBJECTIVE: The goal of this study was to document the use of 16 treatment modalities reported by 290 patients with borderline personality disorder and 72 patients with other axis II disorders over 16 years of prospective follow-up. METHODS: This study built upon previous findings of the McLean Study of Adult Development. Treatment use was assessed at baseline and at eight two-year follow-up periods with a semistructured interview of proven reliability and validity. RESULTS:Patients with borderline personality disorder reported significantly higher rates of use of 12 of the 16 treatment modalities studied. Only four of the 16 treatment modalities were used by roughly the same percentage of patients with borderline personality disorder and those with other axis II disorders: individual therapy, intensive individual therapy, couples or family therapy, and electroconvulsive therapy. In addition, rates of participation in 13 treatment modalities declined significantly over the first eight years of follow-up for those in both study groups. However, the rates of participation in 15 of 16 treatment modalities did not decline significantly over the second eight years of follow-up for those in either study group. CONCLUSIONS: The results of this study suggest that rates of treatment use by patients with borderline personality disorder decline significantly over the short and medium term. They also suggest that these rates remain stable or fail to decline further over the longer term.
Authors: Mary C Zanarini; Frances R Frankenburg; John Hennen; D Bradford Reich; Kenneth R Silk Journal: Am J Psychiatry Date: 2004-11 Impact factor: 18.112
Authors: Mary C Zanarini; Christina M Temes; Alexandra M Ivey; Danielle M Cohn; Lindsey C Conkey; Frances R Frankenburg; Garrett M Fitzmaurice Journal: Psychiatry Res Date: 2017-02-27 Impact factor: 3.222
Authors: Mary C Zanarini; Christina M Temes; Frances R Frankenburg; D Bradford Reich; Garrett M Fitzmaurice Journal: Psychiatry Res Date: 2018-02-20 Impact factor: 3.222
Authors: M Bohus; C Schmahl; S C Herpertz; K Lieb; M Berger; S Roepke; A Heinz; J Gallinat; L Lyssenko Journal: Nervenarzt Date: 2016-07 Impact factor: 1.214
Authors: Mary C Zanarini; Frances R Frankenburg; D Bradford Reich; Garrett M Fitzmaurice Journal: Am J Psychiatry Date: 2016-02-12 Impact factor: 18.112
Authors: Ole Jakob Storebø; Jutta M Stoffers-Winterling; Birgit A Völlm; Mickey T Kongerslev; Jessica T Mattivi; Mie S Jørgensen; Erlend Faltinsen; Adnan Todorovac; Christian P Sales; Henriette E Callesen; Klaus Lieb; Erik Simonsen Journal: Cochrane Database Syst Rev Date: 2020-05-04
Authors: Ole Jakob Storebø; Johanne Pereira Ribeiro; Mickey T Kongerslev; Jutta Stoffers-Winterling; Mie Sedoc Jørgensen; Klaus Lieb; Anthony Bateman; Richard Kirubakaran; Nicolas Dérian; Eirini Karyotaki; Pim Cuijpers; Erik Simonsen Journal: BMJ Open Date: 2021-06-21 Impact factor: 2.692